In the light of the modest activity of unselected treatment of non-small-cell lung cancer (NSCLC), therapeutic targets and biomarkers are urgently needed. Many attempts have been undertaken to find prognostic and predictive markers in NSCLC. To date only histology, i.e. squamous versus non-squamous, and activating epidermal growth factor receptor mutations have entered clinical practice as biomarkers. Excision-repair cross-complementation group I-protein (ERCC1), ribonucleotide reductase regulatory subunit M1 (RRM1) and echinoderm microtubule-associated ligand-anaplastic lymphoma kinase (EML4-ALK) are possible future options as well as genetic signatures. This article covers these relevant matters.
Share this Article
Related Content In Lung Cancer
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
touchREVIEWS in Oncology & Haematology. 2021;17(1): Online ahead of journal publication
The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the treatment of patients without oncogenic drivers. Consequently, the lives of patients with NSCLC have significantly […]
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!